

2024 年度广东省科学技术奖公示表

(青年科技创新奖)

候选人 基本情况	姓名	陈雨沛	工作单位	中山大学肿瘤防治中心		
	职称	研究员	学历	博士	从事专业	肿瘤学
提名者	广东省卫生健康委员会					
提名意见	<p>陈雨沛同志政治立场坚定，坚决拥护中国共产党的领导，具备良好的师德师风。其在学术工作中恪守规范与道德，作风严谨，求真务实，勇于创新，科研成果显著。经核实，其个人背景清晰，无政治思想问题或违法违纪记录。我单位已对申报材料进行严格审查，确认所有内容真实有效，且不涉及涉密信息，特此郑重提名其申报2024年广东省青年科技创新奖。</p>					
候选人的主要 科研业绩	<p>代表性论文 10 篇：</p> <ol style="list-style-type: none"> 1. <u>Chen, Yu-Pei</u>(#); Liu, Xu(#); Zhou, Qin(#); Yang, Kun-Yu(#); Jin, Feng(#); Zhu, Xiao-Dong(#); Shi, Mei(#); Hu, Guo-Qing(#); Hu, Wei-Han(#); Sun, Yan; Wu, Hong-Fen; Wu, Hui; Lin, Qin; Wang, Hui; Tian, Ye; Zhang, Ning; Wang, Xi-Cheng; Shen, Liang-Fang; Liu, Zheng-Zheng; Huang, Jing; Luo, Xiu-Ling; Li, Ling; Zang, Jian; Mei, Qi; Zheng, Bao-Min; Yue, Dan; Xu, Jing; Wu, San-Gang; Shi, Yan-Xia; Mao, Yan-Ping; Chen, Lei; Li, Wen-Fei; Zhou, Guan-Qun; Sun, Rui; Guo, Rui; Zhang, Yuan; Xu, Cheng; Lv, Jia-Wei; Guo, Ying; Feng, Hui-Xia; Tang, Ling-Long(*); Xie, Fang-Yun(*); Sun, Ying(*); Ma, Jun(*). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet</i>, 2021, 398(10297): 303-313. 2. <u>Chen, Yu-Pei</u>(#); Chan, Anthony TC; Le, Quynh-Thu; Blanchard, Pierre; Sun, Ying(*); Ma, Jun(*). Nasopharyngeal carcinoma. <i>Lancet</i>, 2019, 381(12): 1124-1135. 3. <u>Chen, Yu-Pei</u>(#); Wang, Ya-Qin(#); Lv, Jia-Wei(#); Li, Ying-Qin(#); Chua, Melvin; Le, Quynh-Thu; Lee, Nancy; Colevas, A. Dimitrios; Seiwert, Tanguy; Hayes, D. Neil; Riaz, Nadeem; Vermorken, Jan B; O'Sullivan, Brian; He, Qing-Mei; Yang, Xiao-Jing; Tang, Ling-Long; Mao, Yan-Ping; Sun, Ying; Liu, Na(*); Ma, Jun(*). Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. <i>Ann Oncol</i>, 2019, 30(1): 68-75. 4. <u>Chen, Yu-Pei</u>(#); Ismaila, Nofisat; Chua, Melvin LK; Colevas, A. Dimitrios; Haddad, Robert; Huang, Shao Hui; Wee, Joseph TS; Whitley, Alexander C; Yi, Jun-Lin; Yom, Sue S; Chan, Anthony TC; Hu, Chao-Su; Lang, Jin-Yi; Le, Quynh-Thu; Lee, Anne WM; Lee, Nancy; Lin, Jin-Ching; Ma, Brigette; Morgan, Thomas J; Shah, Jatin; Sun, Ying(*); Ma, Jun(*). Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. <i>J Clin Oncol</i>, 2021, 39(7): 840-859. (IF 42.1, 唯一第一, ESI TOP 1%高被引论文) 5. <u>Chen, Yu-Pei</u>(#); Yin, Jian-Hua(#); Li, Wen-Fei(#); Li, Han-Jie(#); Chen, Dong-Ping(#); Zhang, Cui-Juan(#); Lv, Jia-Wei; Wang, Ya-Qin; Li, Xiao-Min; Li, Jun-Yan; Zhang, Pan-Pan; Li, Ying-Qin; He, Qing-Mei; Yang, Xiao-Jing; Lei, Yuan; Tang, Ling-Long; Zhou, Guan-Qun; Mao, Yan-Ping; Wei, Chen; Xiong, Ke-Xu; Zhang, Hong-Bo; Zhu, Shi-Da; Hou, Yong; Sun, Ying; Dean, Michael; Amit, Ido; Wu, Kui(*); Kuang, Dong-Ming(*); Li, Gui-Bo(*); Liu, Na(*); Ma, Jun(*). Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. <i>Cell Res</i>, 2020, 30(11): 1024-1042. 					

6. Wang, Ya-Qin^(#); Wu, Dong-Hong^(#); Wei, Deng-Hui^(#); Shen, Jia-Yi(#); Huang, Zi-Wei^(*); Liang, Xiao-Yu; Cho. William CS; Ma, Jun; Lv, Jia-Wei^(*); **Chen, Yu-Pei^(*)**. TEAD4 is a master regulator of high-risk nasopharyngeal carcinoma. *Sci Adv*, 2023, 9(1): eadd0960.
7. Zhao, Yin^(#); Huang, Shen-Yan^(#); Tan, Xi-Rong; Long, Liu-Fen; He, Qing-Mei; Liang, Xiao-Yu; Bai, Jie-Wen; Li, Qing-Jie; Lin, Jia-Yi; Li, Ying-Qin; Liu, Na; Ma, Jun^(*); **Chen, Yu-Pei^(*)**. N6-Methyladenosine-Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation. *Adv Sci*, 2022, 9(36): e2205091.
8. **Chen, Yu-Pei^(*)(#)**; Lv, Jia-Wei^(#); Mao, Yan-Ping^(#); Li, Xiao-Min^(#); Li, Jun-Yan^(#); Wang, Ya-Qin^(#); Xu, Cheng; Li, Ying-Qin; He, Qing-Mei; Yang, Xiao-Jing; Lei, Yuan; Shen, Jia-Yi; Tang, Ling-Long; Chen, Lei; Zhou, Guan-Qun; Li, Wen-Fei; Du, Xiao-Jing; Guo, Rui; Liu, Xu; Zhang, Yuan; Zeng, Jing; Yun, Jing-Ping; Sun, Ying^(*); Liu, Na^(*); Ma, Jun^(*). Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. *Mol Cancer*, 2021, 20(1):14.
9. Liu, Xu^(#); Zhang, Yuan^(#); Yang, Kun-Yu^(#); Zhang, Ning^(#); Jin, Feng^(#); Zou, Guo-Rong^(#); Zhu, Xiao-Dong^(#); Xie, Fang-Yun^(#); Liang, Xiao-Yu^(#); Li, Li, Wen-Fei; He, Zhen-Yu; Chen, Nian-Yong; Hu, Wei-Han; Wu, Hai-Jun; Shi, Mei; Zhou, Guan-Qun; Mao, Yan-Ping; Guo, Rui; Sun, Rui; Huang, Jing; Liang, Shao-Qiang; Wu, Wei-Li; Su, Zhen; Li, Ling; Ai, Ping; He, Yu-Xiang; Zang, Jian; Chen, Lei; Lin, Li; Huang, Shao-Hui; Xu, Cheng; Lv, Jia-Wei; Li, Ying-Qing; Hong, Shu-Bin; Jie, Yu-Sheng; Li, Hao; Huang, Sai-Wei; Liang, Ye-Lin; Wang, Ya-Qin; Peng, Ying-Lin; Zhu, Jin-Han; Zang, Sheng-Bing; Liu, Song-Ran; Lin, Qing-Guang; Li, Hao-Jiang; Tian, Li; Liu, Li-Zhi; Zhao, Hong-Yun; Lin, Ai-Hua; Li, Ji-Bin; Liu, Na; Tang, Ling-Long^(*); **Chen, Yu-Pei^(*)**; Sun, Ying^(*); Ma, Jun^(*). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. *Lancet*, 2024, 403(10445): 2720-2731.
10. Lv, Jiawei^(#); Xu, Ling-Xin^(#); Li, Zhi-Xuan^(#); Lin, Li^(#); Wu, Chen-Fei^(#); Quan, Ting-Qiu; Zhen, Zi-Cheng; Li, Wen-Fei; Tang, Ling-Long; Mao, Yan-Ping; Chen, Lei; Guo, Rui; Zhang, Lu-Lu; Ai, Xin-Lei; Wu, Shi-Yue; Hao, Meng-Yu; Wei, Denghui; Li, Ji-Bin; Ma, Jun^(*); **Chen, Yu-Pei^(*)**; Zhou, Guan-Qun^(*); Sun, Ying^(*). Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. *Cancer Cell*, 2024, 42(8): 1401-1414.e4.

授权专利 3项：

1. 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统；中国；ZL202010633755.0；中山大学肿瘤防治中心；马骏、陈雨沛、柳娜、孙颖、李文斐、吕佳蔚、王雅琴、李晓敏、李君炎、张磐磐、黎映琴、唐玲珑、毛燕萍、周冠群、何庆梅、杨晓静
2. 预测鼻咽癌免疫治疗疗效的标志物组及应用；中国；ZL202011220045.1；中山大学肿瘤防治中心；马骏、陈雨沛、柳娜、孙颖、吕佳蔚、李君炎、王雅琴、黎映琴、何庆梅、杨晓静
3. 一种针对ASMT/CYP1A2分子的试剂盒在预测实体瘤临床预后和免疫特征中的应用；中国；ZL201910041894.1；中山大学肿瘤防治中心；孙颖、陈雨沛、吕佳蔚、郑子奇